PCR200 Content Validity of FACT-GP5 to Assess Treatment Tolerability in Participants With Progressive, Advanced, Kinase Inhibitor-Naïve, RET-Mutant Medullary Thyroid Cancer: Qualitative Interview Sub-Study of the LIBRETTO-531 Trial
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.2079
https://www.valueinhealthjournal.com/article/S1098-3015(24)02194-6/fulltext
Title :
PCR200 Content Validity of FACT-GP5 to Assess Treatment Tolerability in Participants With Progressive, Advanced, Kinase Inhibitor-Naïve, RET-Mutant Medullary Thyroid Cancer: Qualitative Interview Sub-Study of the LIBRETTO-531 Trial
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)02194-6&doi=10.1016/j.jval.2024.03.2079
First page :
Section Title :
Open access? :
No
Section Order :
11186